	US 12,351,645 B2
	Anti-carbonic anhydrase IX antibody
Bor-Yu Tsai, New Taipei (TW); and Wei-Ting Hsu, Taipei (TW)
Assigned to NAVI BIO-THERAPEUTICIS, INC., Kaohsiung (TW)
Appl. No. 17/051,635
Filed by NAVI BIO-THERAPEUTICS, INC., Kaohsiung (TW)
PCT Filed May 6, 2019, PCT No. PCT/US2019/030807 § 371(c)(1), (2) Date Oct. 29, 2020, PCT Pub. No. WO2020/226612, PCT Pub. Date Nov. 12, 2020.
Prior Publication US 2022/0049012 A1, Feb. 17, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/40 (2006.01)

CPC C07K 16/30 (2013.01) [C07K 16/40 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C12Y 402/01001 (2013.01)]

18 Claims

1. An isolated anti-carbonic anhydrase IX (CAIX) antibody or antigen-binding portion thereof, comprising:

a light chain complementarity determining region 1 (L-CDR1) of SEQ ID NO:4; a light chain CDR2 (L-CDR2) of SEQ ID NO:5; and a light chain CDR3 (L-CDR3) of SEQ ID NO:3; and

a heavy chain CDR1 (H-CDR1) of SEQ ID NO:12; a heavy chain CDR2 (H-CDR2) of SEQ ID NO:13; and a heavy chain CDR3 (H-CDR3) of SEQ ID NO:14; such that said isolated antibody or antigen-binding portion thereof binds to CAIX.